Patents by Inventor David S. Garvey

David S. Garvey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of squalene synthetase and protein farnesyltransferase
    Patent number: 5783593
    Abstract: The present invention provides a compound of the formula ##STR1## which inhibit squalene synthetase and cholesterol biosynthesis and are useful in the treatment of e.g., hyperlipidaemia, atherosclerosis, or fungal infections, processes for the preparation of the compounds of the invention, intermediates useful in these processes, and pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: April 29, 1996
    Date of Patent: July 21, 1998
    Assignee: Abbott Laboratories
    Inventors: William R. Baker, Saul H. Rosenberg, Anthony K. L. Fung, Todd W. Rockway, Stephen A. Fakhoury, David S. Garvey, B. Gregory Donner, Stephen J. O'Connor, Rajnandan N. Prasad, Wang Shen, David M. Stout, Gerard M. Sullivan
  • 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission
    Patent number: 5733912
    Abstract: 7a-Substituted hexahydro-1H-pyrrolizine compounds having the formula ##STR1## wherein A is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to selectively control synaptic transmission in mammals.
    Type: Grant
    Filed: February 19, 1997
    Date of Patent: March 31, 1998
    Assignee: Abbott Laboratories
    Inventors: James T. Wasicak, David S. Garvey, Mark W. Holladay, Nan-Horng Lin, Keith B. Ryther
  • Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
    Patent number: 5703073
    Abstract: Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compositions are disclosed. The compounds and compositions protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal antiinflammatory drugs.
    Type: Grant
    Filed: October 13, 1995
    Date of Patent: December 30, 1997
    Assignee: NitroMed, Inc.
    Inventors: David S. Garvey, L. Gordon Letts, H. Burt Renfroe, Sang William Tam
  • Inhibitors of protein farnesyltransferase and squalene synthase
    Patent number: 5631401
    Abstract: The present invention provides a compound of the formula ##STR1## or a pharmaceutically acceptable salt thereof, which are useful in inhibiting protein farnesyltransferase and the farnesylation of the oncogene protein Ras or inhibiting de novo squalene production resulting in the inhibition of cholesterol biosynthesis, processes for the preparation of the compounds of the invention in addition to intermediates useful in these processes, a pharmaceutical composition, and to methods of using such compounds.
    Type: Grant
    Filed: January 24, 1995
    Date of Patent: May 20, 1997
    Assignee: Abbott Laboratories
    Inventors: Herman H. Stein, William R. Baker, Anthony K. L. Fung, Saul H. Rosenberg, Todd W. Rockway, Stephen A. Fakhoury, David S. Garvey, B. Gregory Donner, William J. McClellan, Stephen J. O'Connor, Rajnandan Prasad, Wang Shen, Gerard M. Sullivan
  • Isoxazole, isothiazole and pyrazole compounds that enhance cognitive function
    Patent number: 5409946
    Abstract: Novel isoxazole isothiazole and pyrazole compounds of the formula: ##STR1## wherein A, R.sup.1, and R.sup.2 are specifically defined, or pharmaceutical salts thereof, are selective and potent cholinergic ligands at neuronal nicotinic receptors, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function, as well as in the treatment of alcohol intoxication and petit real absence epilepsy.
    Type: Grant
    Filed: September 8, 1993
    Date of Patent: April 25, 1995
    Assignee: Abbott Laboratories
    Inventors: David S. Garvey, George M. Carrera, Jr., Stephen P. Arneric, Youe-Kong Shue, Nan-Horng Lin, Yun He, Edmund L. Lee, Suzanne A. Lebold
  • Peptide analog type-B CCK receptor ligands
    Patent number: 5340802
    Abstract: Peptide analog type-B CCK receptor ligands or pharmaceutically-acceptable salts thereof, which are useful for treating central nervous system disorders, substance abuse, gastrointestinal disorders, endocrine disorders, eating-related disorders and for the treatment of shock, respiratory and cardiocirculatory insufficiencies.
    Type: Grant
    Filed: January 29, 1993
    Date of Patent: August 23, 1994
    Assignee: Abbott Laboratories
    Inventors: Kazumi Shiosaki, Alex M. Nadzan, David S. Garvey, Youe-Kong Shue, Mark S. Brodie, Mark W. Holladay, John Y.-L. Chung, Michael D. Tufano, Paul D. May
  • Aza-spirocyclic compounds that enhance cholinergic neurotransmission
    Patent number: 5221675
    Abstract: Aza-spirocyclic compounds of formula (I) ##STR1## which enhance cortical cholinergic neurotransmission.
    Type: Grant
    Filed: February 26, 1991
    Date of Patent: June 22, 1993
    Assignee: Abbott Laboratories
    Inventors: John Y. L. Chung, David S. Garvey